Anaplastic thyroid cancer (ATC) accounts for only 1-3% of thyroid malignancies but can cause up to 50% of thyroid cancer deaths. It is a rare but extremely aggressive and undifferentiated thyroid tumor. Compressive symptoms, such as trouble breathing or swallowing, are common, and it usually manifests as a painful, quickly growing neck lump. After diagnosis, ATC has a median lifespan of only three to six months due to its rapid spread to distant organs and lymph nodes. The anaplastic thyroid cancer pipeline analysis by Expert Market Research focuses on various treatment options for this disease.
Major companies involved in the anaplastic thyroid cancer pipeline analysis include Hoffmann-La Roche, AffyImmune Therapeutics, Inc. and Shanghai Henlius Biotech, among others.
Leading drugs currently in the pipeline include Entrectinib, and AIC100 CAR T Cells, others.
Increased investment in research and development, along with regulatory support, is accelerating clinical trials and new treatment approvals.
The Anaplastic Thyroid Cancer Pipeline Analysis Report by Expert Market Research gives comprehensive insights into anaplastic thyroid cancer therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for anaplastic thyroid cancer therapeutics. The anaplastic thyroid cancer report assessment includes the analysis of over 15 pipeline drugs and 10+ companies. The anaplastic thyroid cancer pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with anaplastic thyroid cancer treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to anaplastic thyroid cancer.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Multiple genetic mutations, including those in the BRAF, RAS, TP53, PIK3CA, and PTEN genes, can accumulate in differentiated thyroid tumors to cause anaplastic thyroid cancer (ATC). These mutations lead to rapid dedifferentiation, genomic instability, and aggressive tumor behavior. Rapid progression and resistance to traditional treatments result from ATC cells' invasion of local tissues, loss of normal thyroid characteristics, and strong mitotic activity. Its etiology is further influenced by epigenetic modifications and compromised DNA repair.
Although most cases of anaplastic thyroid carcinoma are incurable at diagnosis, treatment options are multimodal and frequently involve surgery, radiation therapy, and chemotherapy. Doxorubicin, cisplatin, paclitaxel, or docetaxel are examples of chemotherapy regimens. Occasionally, radiation is used in conjunction with these drugs as chemoradiation. Immunotherapy and targeted treatments, such as dabrafenib and trametinib for cancers with a BRAF mutation, may be employed. Palliative care is essential for improving quality of life and symptom reduction, particularly in cases of advanced illness.
Although it accounts for only 1% to 2% of all thyroid malignancies, anaplastic thyroid carcinoma (ATC) is responsible for 14–50% of thyroid cancer-related deaths. It primarily affects older adults, with a mean age of about 70, and has an incidence of about 1 to 2 cases per million people each year in the United States. Globally, the incidence of ATC has stayed constant or even significantly decreased, despite an increase in thyroid cancer rates overall. About 60–70% of cases are female, and the majority of those affected are Caucasian.
This section of the report covers the analysis of anaplastic thyroid cancer drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, in the Anaplastic Thyroid Cancer pipeline, 67% of candidates lie in Phase II while the remaining lie in Phase I. Thus, demonstrating a concentrated focus toward potential treatments.
The drug molecule categories covered under the anaplastic thyroid cancer pipeline analysis include antibodies, antisense oligonucleotides, immunotherapies, monoclonal antibodies, peptides, proteins, recombinant proteins, small molecules, stem cells and vaccines. The anaplastic thyroid cancer report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for anaplastic thyroid cancer.
The EMR report for the anaplastic thyroid cancer pipeline analysis covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in anaplastic thyroid cancer clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for anaplastic thyroid cancer. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of anaplastic thyroid cancer drug candidates.
Entrectinib (Rozlytrek), developed by Hoffmann-La Roche, is a selective tyrosine kinase inhibitor targeting NTRK, ROS1, and ALK gene fusions. In a Phase 1/2 trial, it is being evaluated in pediatric patients with solid tumors harboring these fusions. While specific data on anaplastic thyroid cancer (ATC) is limited, a case report highlighted its potential with a previously unresectable NTRK-positive ATC tumor responding to entrectinib, and enabling successful surgical resection.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Anaplastic Thyroid Cancer Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for anaplastic thyroid cancer. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into anaplastic thyroid cancer collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share